Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1Phase 2 1

Status

Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

CNS 3Endocrine 2NET 1

Conditions

Neuroendocrine Tumors 3Neuroblastoma 3Pheochromocytoma 2Paraganglioma 2Neural crest tumor 1Ganglioneuroblastoma 1

Interventions

Cyclophosphamide 101Etoposide 60Carboplatin 55Vincristine 51Filgrastim 49Topotecan 44Temozolomide 44Melphalan 44Isotretinoin 44Doxorubicin 44Irinotecan 42Cisplatin 35Peripheral Blood Stem Cell Transplantation 31dinutuximab 29Radiotherapy 29Granulocyte Colony-Stimulating Factor 29sargramostim 283-Iodobenzylguanidine 27Granulocyte-Macrophage Colony-Stimulating Factor 25Busulfan 22Magnetic Resonance Spectroscopy 19aldesleukin 18Thiotepa 18fludarabine 17Interleukin-2 17humanized 3F8 anti-GD2 monoclonal antibody 16etoposide phosphate 16Ifosfamide 15naxitamab 14fludarabine phosphate 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Neuroblastoma × 3-fluorobenzylguanidine × Clear all
NCT04724369 2026-04-03

Open-Label Study of 18F-mFBG for Imaging Neuroblastoma

Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)

Phase 3 Active not recruiting
43 enrolled
CNS

Neuroblastoma

NCT06233903 2025-01-21

18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System

Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)

Phase 2 Withdrawn
CNSEndocrine

Neuroblastoma, Paraganglioma, Pheochromocytoma

NCT05069220 2024-03-01

18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor

Peking Union Medical College Hospital

Phase EARLY_PHASE1 Recruiting
150 enrolled
CNSEndocrineNET

Neuroblastoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡